Selected article for: "infection number and mortality rate"
Author: Kim, Ah Young; Jung, Se Yong; Choi, Jae Young; Kim, Gi Beom; Kim, Young-Hwue; Shim, Woo Sup; Kang, I-Seok; Jung, Jo Won
Title: Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases
  • Document date: 2016_9_28
    • ID: 0ipmswy4_6
    Snippet: We also investigated the patients hospitalized for RSV infection despite receiving palivizumab; factors included their age and calendar month at RSV infection, and factors related to infection severity. For infection severity, we reviewed their visit to the emergency department and ICU admissions, hospital and ICU length of stay, oxygen requirements, mechanical ventilation use, and delay of elective operation. According to different types of hear.....
    Document: We also investigated the patients hospitalized for RSV infection despite receiving palivizumab; factors included their age and calendar month at RSV infection, and factors related to infection severity. For infection severity, we reviewed their visit to the emergency department and ICU admissions, hospital and ICU length of stay, oxygen requirements, mechanical ventilation use, and delay of elective operation. According to different types of heart disease, the rate of RSV infection, all-cause and RSV related mortality, and doses of palivizumab were analyzed. RSV infection was confirmed by direct fluorescent antibody staining, culture, or reverse-transcriptase polymerase chain reaction on nasopharyngeal swabs or aspirates according to policy of each center. We noted the number of patients with breakthrough RSV infection and mortality, by comparison to doses of palivizumab prophylaxis according to type of CHD.

    Search related documents:
    Co phrase search for related documents
    • oxygen requirement and reverse transcriptase: 1, 2, 3, 4, 5, 6
    • oxygen requirement and reverse transcriptase polymerase: 1, 2, 3, 4, 5, 6
    • oxygen requirement and RSV infection: 1, 2, 3, 4, 5, 6
    • oxygen requirement and stay ICU length: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • oxygen requirement and stay ICU length hospital: 1, 2, 3, 4, 5
    • palivizumab dose and RSV infection: 1, 2, 3
    • palivizumab dose and rsv infection rate: 1
    • palivizumab prophylaxis and RSV infection: 1, 2, 3, 4, 5, 6, 7, 8
    • palivizumab receive and RSV infection: 1, 2
    • reverse transcriptase and RSV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • reverse transcriptase and rsv infection rate: 1
    • reverse transcriptase and stay ICU length: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • reverse transcriptase and stay ICU length hospital: 1, 2, 3, 4, 5
    • reverse transcriptase polymerase and RSV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • reverse transcriptase polymerase and rsv infection rate: 1
    • reverse transcriptase polymerase and stay ICU length: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • reverse transcriptase polymerase and stay ICU length hospital: 1, 2, 3, 4, 5
    • RSV infection and stay ICU length: 1, 2
    • RSV infection and stay ICU length hospital: 1, 2